secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001104659-24-064883
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus launches warrant exchange offer at 0.3 shares per warrant; seeks to reduce dilution
--------------------------------------------------------------------------------

- Offering up to 4,264,532 common shares for up to 14.2M warrants (0.30 per warrant).
- 34.8% of Public Warrants pre-committed; needs ~15.3% more to meet majority threshold.
- Consent solicitation seeks amendment allowing forced conversion at 0.27 shares (10% discount).
- Expiration date: June 25, 2024; Oppenheimer & Co. is dealer manager.
- Company aims to simplify capital structure and reduce future dilutive impact of warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924064883/0001104659-24-064883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924064883/tm2415396d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-064883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer